NANOVIRICIDES, INC. (NNVC) Form S-3 — Aug 21, 2026
NanoViricides filed a Form S-3 registering the resale of 2,516,339 shares of common stock issuable upon exercise of Common Stock Purchase Warrants held by Armistice Capital Master Fund Ltd, the investor in the company's July 24, 2026 registered direct offering. The company will receive no proceeds from Armistice's resales of these shares. If the Common Warrants are exercised in full for cash at $1.75 per share, NanoViricides would receive approximately $4.4 million in gross proceeds. However, the stock's last reported sale price was $1.34 on August 19, 2026, leaving the warrants out of the money, and the company cautions they may expire unexercised.
Key figures
- Gross Proceeds
- Approximately $4.4 million to the company ONLY if Common Warrants are exercised in full for cash; $0 from Selling Stockholder resales
- Shares Offered
- 2516339
- Warrant term
- exercisable six months from issuance, expires five and one-half years from issuance
- Sec registration fee
- 608.14
- Warrant exercise price
- 1.75
- Shares outstanding prior
- 25527353
- July 2026 prefunded warrants
- 100000
- Existing warrants outstanding
- 8480768
- July 2026 offering shares sold
- 2416339
- Series a preferred outstanding
- 918809
- July 2026 offering gross proceeds
- $3.8 million
- July 2026 offering price per share
- 1.53
- Last reported sale price aug 19 2026
- 1.34
- Registration fee table max aggregate
- 4403593.25
- Implied dilution percent on full exercise
- 9.9
- Existing warrants weighted avg exercise price
- 1.86
- Shares outstanding if warrants fully exercised
- 28043692
Price after filing
Close on the filing date to close N calendar days later (from $1.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.